Transfusion Medicine Reviews
Volume 21, Issue 1 , Pages 58-71 , January 2007

Blood Group Antibodies and Their Significance in Transfusion Medicine

  • Joyce Poole

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Joyce Poole, MRCPath CSci FIBMS, International Blood Group Reference Laboratory, Southmead Road, BS10 5ND Bristol, UK.
    • ,
  • Geoff Daniels

References 

  1. Klein HG, Anstee DJ. Blood transfusion in clinical medicine. 11th ed.. Oxford (UK): Blackwell Publishing; 2005;
  2. Issitt PD, Anstee DJ. Applied blood group serology. 4th ed.. Durham (NC): Montgomery Scientific Publications; 1998;
  3. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583–590
  4. Hadley AG, Turner C. Pathophysiology of the alloimmune cytopenias. In:  Hadley A,  Soothill P editor. Alloimmune disorders of pregnancy. Cambridge (UK): Cambridge University Press; 2002;p. 1–20
  5. Vaughan JI, Warwick R, Letsky E, et al. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am. J. Obstet. Gynecol. 1994;171:247–252
  6. Weiner CP, Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am. J. Obstet. Gynecol. 1996;174:547–551
  7. Frohn C, Dümbgen L, Brand J-M, et al. Probability of anti-D development in D− patients receiving D+ RBCs. Transfusion. 2003;43:893–898
  8. Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell alloimmunization following transfusion. Vox Sang. 1996;71:216–220
  9. Olujohungbe A, Hambleton I, Stephens L, et al. Red cell antibodies in patients with homozygous sickle cell disease: A comparison of patients in Jamaica and the United Kingdom. Br. J. Haematol. 2001;113:661–665
  10. Freidman DF, Kim HC, Manno CS. Hyper-hemoloysis associated with red cell transfusion in sickle cell disease. Transfusion. 1993;33:(Suppl. 14S)
  11. Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion. 1997;37:357–361
  12. King KE, Shirey RS, Lankiewicz ME, et al. Delayed hemolytic transfusion reactions in sickle cell disease: Simultaneous destruction of recipients' red cells. Transfusion. 1997;37:376–381
  13. Win N, Doughty H, Telfer P, et al. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion. 2001;41:323–328
  14. Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion. 1997;37:382–392
  15. Chapman JF, Elliott C, Knowles SM, et al. Guidelines for compatibility procedures in blood transfusion laboratories. Working Party of the British Committee for Standards in Haematology Blood Transfusion Task Force. Transfus. Med. 2004;14:59–73
  16. Garratty G. Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Transfus. Med. Rev. 1990;4:297–312
  17. Zupanska B, Brojer E, Richards Y, et al. Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn. Vox Sang. 1989;56:247–253
  18. Nance SJ, Nelson JM, Horenstein J, et al. Monocyte monolayer assay: An efficient noninvasive technique for predicting the severity of haemolytic disease of the new-born. Am. J. Clin. Pathol. 1986;92:89–92
  19. Garner SF, Gorick BD, Lai WYY, et al. Prediction of the severity of haemolytic disease of the newborn. Vox Sang. 1995;68:169–176
  20. Engelfreit CP, Ouwehand WH. ADCC and other cellular bioassays for predicting the clinical significance of red cell alloantibodies. Ballieres Clin Hematol. 1990;3:321–337
  21. Urbaniak SJ, Greiss MA, Crawford RJ, et al. Prediction of the outcome of rhesus haemolytic disease of the newborn: Additional information using an ADCC assay. Vox Sang. 1984;46:323–329
  22. Hadley AG, Wilkes A, Goodrick J, et al. The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn. Br. J. Obstet. Gynaecol. 1998;105:231–234
  23. International Committee for Standardization in Hematology . Recommended methods for radioisotope red cell survival studies. Br. J. Haematol. 1980;45:659–666
  24. Nance SJ, Arndt P, Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion. 1987;27:449–452
  25. Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion. 2004;44:1273–1281
  26. Daniels G, Poole J, de Silva M, et al. The clinical significance of blood group antibodies. Transfus. Med. 2002;12:287–295
  27. Hadley A, Wilkes A, Poole J, et al. A chemiluminescence test for predicting the outcome of transfusing incompatible blood. Transfus. Med. 1999;9:337–342
  28. Daniels G. Human blood groups. 2nd ed.. Oxford (UK): Blackwell Science; 2002;
  29. Hardman JT, Beck ML. Hemagglutination in capillaries: correlation with blood group specificity and IgG subclass. Transfusion. 1981;21:343–346
  30. Pineda AA, Vamvakas EC, Gorden LD, et al. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion. 1999;39:1097–1103(and corrections in Transfusion 2000;40:891)
  31. Hoppe B, Pastucha L, Seltsam A, et al. Acute haemolytic transfusion reactions due to weak antibodies that in vitro did not seem to be clinically significant. Vox Sang. 2002;82:207–210
  32. Nance ST. Do HLA antibodies cause hemolytic transfusion reactions or decreased RBC survival? Editorial. Transfusion. 2004;43:687–690
  33. Benson K, Agosti SJ, Latoni-Benedetti GE, et al. Acute and delayed hemolytic transfusion reactions secondary to HLA alloimmunization. Transfusion. 2003;43:753–757
  34. Takeuchi C, Ohto H, Miura S, et al. Delayed and acute hemolytic transfusion reactions resulting from red cell antibodies and red-cell reactive HLA antibodies. Transfusion. 2005;45:1925–1929
  35. Anstee D, Levene C, Mallory D, et al. Rare Blood. An ISBT Working Party Report on Rare Blood Donors. Vox Sang. 1999;77:58–62
  36. Seltsam A, Wagner FF, Salama A, et al. Antibodies to high-frequency antigens may decrease the quality of transfusion support: an observational study. Transfusion. 2003;43:1563–1566
  37. National Institute for Clinical Excellence . Technology appraisal guidance 41. Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women. London: NICE; 2002;
  38. Daniels G. Blood group antibodies in haemolytic disease of the fetus and newborn. In:  Hadley A,  Soothill P editor. Alloimmune disorders of pregnancy. Cambridge (UK): Cambridge University Press; 2002;p. 21–40
  39. Garner SF, Devenish A, Barber H, et al. The importance of monitoring ‘enzyme-only’ red cell antibodies during pregnancy. Vox Sang. 1991;61:219–220
  40. Caine ME, Mueller-Heubach E. Kell sensitization in pregnancy. Am. J. Obstet. Gynecol. 1986;154:85–90
  41. Daniels G, Hadley A, Green CA. Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion. 2003;43:115–116(letter)
  42. Goodrick MJ, Hadley AG, Poole G. Haemolytic disease of the fetus and newborn due to anti-Fya and the potential clinical value of Duffy genotyping in pregnancies at risk. Transfus. Med. 1997;7:301–304
  43. Arndt PA, Garratty G, Daniels G, et al. Late onset neonatal anemia due to anti-Ge: possible association with destruction of erythroid progenitors. Transfus. Med. 2005;15:125–132
  44. Lindström K, von dem Borne AEGK, Breimer ME, et al. Glycosphingolipid expression in spontaneously aborted fetuses and placenta from blood group p women. Evidence for placenta being the primary target for anti-Tja-antibodies. Glycoconj. J. 1992;9:325–329
  45. Le Masne A, Vachée A, Horbey C, et al. Forme sévère de maladie hémolytique néonatale par allo-immunisation anti-Vel. Arch. Fr. Pediatr. 1992;49:899–901
  46. Daniels G, Finning K, Martin P, et al. Fetal blood group genotyping from DNA from maternal plasma: An important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang. 2004;87:225–232
  47. van der Schoot CE. Molecular diagnostics in immunohaematology. Vox Sang. 2004;87:189–192(Suppl 2)
  48. Anstee DJ. Goodbye to agglutination and all that?. Transfusion. 2005;45:652–653

PII: S0887-7963(06)00061-7

doi: 10.1016/j.tmrv.2006.08.003

Transfusion Medicine Reviews
Volume 21, Issue 1 , Pages 58-71 , January 2007

Article Tools